Patents by Inventor Roger Heim
Roger Heim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220313822Abstract: The present disclosure relates to near-infrared (NIR) photoimmunotherapy (PIT) for treating a subject having a cancer, such as a cancer comprising a first tumor or a primary tumor, metastatic tumor cells and/or invasive tumor cells. The method includes administering to the subject a targeting molecule that binds CD25 conjugated with phthalocyanine dye, such as IR700, and administering an immune checkpoint inhibitor such as an anti PD-1 antibody, followed by illuminating the first tumor or primary tumor with a wavelength of light suitable for the activation of the phthalocyanine dye.Type: ApplicationFiled: July 29, 2020Publication date: October 6, 2022Applicant: Rakuten Medical, Inc.Inventors: Miguel GARCIA-GUZMAN, Roger HEIM, Jerry FONG
-
Publication number: 20220160871Abstract: Provided are methods involving the use of biomarkers, in relation to photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on tumor cell, for example, an IR700-antibody conjugate, and combination therapies, for example, that include photoimmunotherapy and an additional therapeutic agent, such as an immune modulating agent. In some aspects, the provided embodiments can be used to identify or select subjects for photoimmunotherapy and/or the combination therapy, or to assess the likelihood of response to photoimmunotherapy and/or to the additional therapeutic agents. Features of the methods and uses provide various advantages, such as improved efficacy. In some aspects, the provided embodiments can be used to provide personalized medicine and tailored therapy regimens for subjects.Type: ApplicationFiled: March 27, 2020Publication date: May 26, 2022Applicant: Rakuten Medical, Inc.Inventors: Miguel GARCIA-GUZMAN, Roger HEIM, Eileen Sun CHIN, Jerry FONG, Deepak YADAV, Nikolai SUSLOV, C. Daniel DE MAGALHAES FILHO, Chung-Wein LEE
-
Publication number: 20220105184Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.Type: ApplicationFiled: September 16, 2021Publication date: April 7, 2022Applicant: Rakuten Medical, Inc.Inventors: Merrill BIEL, Lewis R. MAKINGS, Roger HEIM, Miguel GARCIA-GUZMAN, Eileen Sun CHIN, Deepak YADAV, Jerry FONG
-
Publication number: 20210401985Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.Type: ApplicationFiled: September 8, 2021Publication date: December 30, 2021Applicant: Rakuten Medical, Inc.Inventors: Merrill BIEL, Lewis R. Makings, Roger Heim, Miguel Garcia-Guzman, Eileen Sun Chin, Deepak Yadav, Jerry Fong
-
Publication number: 20210401986Abstract: Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.Type: ApplicationFiled: September 8, 2021Publication date: December 30, 2021Applicant: Rakuten Medical, Inc.Inventors: Lewis R. MAKINGS, Roger HEIM, Miguel GARCIA-GUZMAN, Eileen Sun CHIN, Deepak YADAV, Jerry FONG
-
Patent number: 11147875Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.Type: GrantFiled: May 23, 2019Date of Patent: October 19, 2021Assignee: Rakuten Medical, Inc.Inventors: Merrill Biel, Roger Heim, Miguel Garcia-Guzman
-
Patent number: 11141483Abstract: Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.Type: GrantFiled: August 18, 2016Date of Patent: October 12, 2021Assignee: Rakuten Medical, Inc.Inventors: Lewis R. Makings, Roger Heim, Miguel Garcia-Guzman
-
Patent number: 10556892Abstract: Disclosed herein, inter alia, are compositions and methods for modulating the activity of N-acylethanolamine acid amidase for the treatment of a pathological state, including pain, an inflammatory condition, or a neurodegenerative disorder.Type: GrantFiled: May 16, 2017Date of Patent: February 11, 2020Assignees: The Regents of the University of California, Fondazione Istituto Italiano di TechnologiaInventors: Daniele Piomelli, Rita Scarpelli, Marco Migliore, Roger Heim, Miguel Garcia-Guzmàn
-
Publication number: 20190282696Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.Type: ApplicationFiled: May 23, 2019Publication date: September 19, 2019Applicant: Rakuten Medical, Inc.Inventors: Merrill BIEL, Roger HEIM, Miguel GARCIA-GUZMAN
-
Publication number: 20190015510Abstract: Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.Type: ApplicationFiled: August 18, 2016Publication date: January 17, 2019Applicants: Aspyrian Therapeutics, Inc., Aspyrian Therapeutics, Inc.Inventors: Lewis R. MAKINGS, Roger HEIM, Miguel GARCIA-GUZMAN, Eileen Sun CHIN, Deepak YADAV, Jerry FONG
-
Publication number: 20180250405Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.Type: ApplicationFiled: August 18, 2016Publication date: September 6, 2018Applicant: Aspyrian Therapeutics, Inc.Inventors: Merrill BIEL, Lewis R. MAKINGS, Roger HEIM, Miguel GARCIA-GUZMAN, Eileen Sun CHIN, Deepak YADAV, Jerry FONG
-
Patent number: 8679742Abstract: This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.Type: GrantFiled: November 4, 2009Date of Patent: March 25, 2014Assignees: The Regents of the University of California, Life Technologies CorporationInventors: Roger Y. Tsien, Roger Heim, Andrew Cubitt
-
Publication number: 20100233726Abstract: This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.Type: ApplicationFiled: November 4, 2009Publication date: September 16, 2010Applicants: The Regents of the University of California, Invitrogen CorporationInventors: Roger Y. Tsien, Roger Heim, Andrew Cubitt
-
Patent number: 7560287Abstract: Engineered fluorescent proteins, nucleic acids encoding them and methods of use are provided.Type: GrantFiled: August 23, 2004Date of Patent: July 14, 2009Assignees: The Regents of the University of California, State of Oregon acting by and through the State Board of Higher Education on behalf of the University of OregonInventors: Roger Y. Tsien, S. James Remington, Andrew B. Cubitt, Roger Heim, Mats F. Ormö
-
Publication number: 20050079525Abstract: Engineered fluorescent proteins, nucleic acids encoding them and methods of use are provided.Type: ApplicationFiled: August 23, 2004Publication date: April 14, 2005Inventors: Roger Tsien, S. Remington, Andrew Cubitt, Roger Heim, Mats Ormo
-
Patent number: 6803188Abstract: This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.Type: GrantFiled: January 31, 1996Date of Patent: October 12, 2004Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, Roger Heim
-
Patent number: 6800733Abstract: Modifications in the sequence of Aequorea wild-type GFP provide products having markedly different excitation and emission spectra from corresponding products from wild-type GFP. In one class of modifications, the product derived from the modified GFP exhibits an alteration in the ratio of two main excitation peaks observed with the product derived from wild-type GFP. In another class, the product derived from the modified GFP fluoresces at a shorter wavelength than the corresponding product from wild-type GFP. In yet another class of modifications, the product derived from the modified GFP exhibits only a single excitation peak and enhanced emission relative to the product derived from wild-type GFP.Type: GrantFiled: December 17, 2001Date of Patent: October 5, 2004Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, Roger Heim
-
Patent number: 6780975Abstract: Engineered fluorescent proteins, nucleic acids encoding them and methods of use are provided.Type: GrantFiled: February 5, 2002Date of Patent: August 24, 2004Assignees: The Regents of the University of California, Vertex Pharmaceuticals (San Diego) LLC, State of Oregon Acting by and through the State Board of Higher Education on behalf of the University of OregonInventors: Roger Y. Tsien, S. James Remington, Andrew B. Cubitt, Roger Heim, Mats F. Ormö
-
Publication number: 20030036178Abstract: Engineered fluorescent proteins, nucleic acids encoding them and methods of use are provided.Type: ApplicationFiled: February 5, 2002Publication date: February 20, 2003Applicant: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, James S. Remington, Andrew B. Cubitt, Roger Heim, Mats F. Ormo
-
Publication number: 20020164674Abstract: This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.Type: ApplicationFiled: January 25, 2002Publication date: November 7, 2002Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Roger Y. Tsien, Roger Heim, Andrew Cubitt